It has been reported that the aromatase inhibitor letrozole can inhibit the expression of SRC-1 in functional areas of the brain, which may induce neurological disorders [40]; in addition, SRC-1 may modulate hippocampal synaptic plasticity by regulating synaptic protein PSD-95 expression and estrogen signalling [41]. The gene discussed is NCOA1; the disease is nervous system disorder.